| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | 4.749 | 20.630 | 38.466 | 41.089 | 60.622 | 58.698 | 57.726 |
| Total Income - EUR | - | - | - | 4.750 | 20.638 | 38.538 | 41.126 | 60.633 | 58.777 | 57.751 |
| Total Expenses - EUR | - | - | - | 71 | 4.543 | 6.463 | 9.164 | 7.407 | 11.317 | 31.605 |
| Gross Profit/Loss - EUR | - | - | - | 4.679 | 16.095 | 32.075 | 31.962 | 53.226 | 47.460 | 26.146 |
| Net Profit/Loss - EUR | - | - | - | 4.537 | 15.829 | 31.691 | 31.551 | 52.620 | 46.872 | 25.568 |
| Employees | - | - | - | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Pharmacovigilance Cotimed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | 79 | 78 | 670 | 409 | 411 | 409 | 1.518 |
| Current Assets | - | - | - | 5.064 | 20.732 | 47.193 | 32.527 | 52.976 | 46.849 | 24.655 |
| Inventories | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | 613 | 2.938 | 4.518 | 5.375 | 44.421 | 44.541 | 20.168 |
| Cash | - | - | - | 4.451 | 17.794 | 42.675 | 27.152 | 8.555 | 2.309 | 4.486 |
| Shareholders Funds | - | - | - | 4.580 | 20.320 | 47.262 | 31.599 | 52.668 | 46.920 | 25.617 |
| Social Capital | - | - | - | 0 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | 563 | 490 | 601 | 1.337 | 718 | 338 | 556 |
| Income in Advance | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "9609 - 9609" | |||||||||
| CAEN Financial Year |
9609
|
|||||||||
Comments - Pharmacovigilance Cotimed S.r.l.